Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01771679Phase 1Unknown

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging

Role: lead

NCT02833792Phase 2Unknown

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

Role: lead

NCT04780685Phase 2Unknown

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

Role: lead

NCT02467387Phase 2Completed

A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure

Role: collaborator

NCT01297413Phase 1Completed

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

Role: lead

NCT01770613Phase 2Withdrawn

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

Role: lead

All 6 trials loaded